PRAVEEN MOOLAMALLA: Open Payments
NPI 1114935954 · MCKINNEY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,165 in 56 payments from 9 companies in 2025. Trend: 2023 $796 · 2024 $768 · 2025 $1,165
Food & beverage: $1,165
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $348 |
| E.R. Squibb & Sons, L.L.C. | 13 | $261 |
| Otsuka America Pharmaceutical, Inc. | 9 | $196 |
| Vanda Pharmaceuticals Inc. | 5 | $108 |
| Supernus Pharmaceuticals, Inc. | 4 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Alkermes, Inc. | 3 | $55 |
| Lundbeck LLC | 1 | $28 |
| Neos Therapeutics, LP | 1 | $14 |
Products named: VRAYLAR, COBENFY, REXULTI, Qelbree, FANAPT, TRINTELLIX, HETLIOZ, ARISTADA.
Industry payments across TX — which companies pay providers there.
